TMC NEWS

TMCNET eNEWSLETTER SIGNUP

Ocular Therapeutix Prices Initial Public Offering

Ocular Therapeutix, a biopharmaceutical company focused on the
development and commercialization of innovative therapies for diseases
and conditions of the eye, announced today the pricing of its initial
public offering of 5,000,000 shares of its common stock at a public
offering price of $13 per share, before underwriting discounts and
commissions. All of the shares in the offering are being sold by Ocular.
Ocular's common stock has been approved for listing on the NASDAQ Global
Market and is expected to begin trading under the ticker symbol "OCUL"
on July 25, 2014. In addition, Ocular has granted the underwriters an
option for a period of 30 days to purchase, at the public offering price
less the underwriting discount, up to 750,000 additional shares of
common stock to cover over-allotments.

Morgan Stanley & Co., Cowen and Company and RBC Capital Markets are
acting as joint book-running managers of the offering. Oppenheimer& Co.
is acting as a co-manager. A registration statement relating to these
securities was declared effective by the U.S. Securities and Exchange
Commission on July 24, 2014. The offering is being made only by means of
a prospectus, copies of which can be obtained from Morgan Stanley & Co.
LLC, attention: Prospectus Department, 180 Varick Street, 2nd Floor, New
York, New York 10014; Cowen and Company, LLC, c/o Broadridge Financial
Services, attention: Prospectus Department, 1155 Long Island Avenue,
Edgewood, NY, 11717; or RBC Capital Markets, LLC, attention: Equity
Syndicate, Three World Financial Center, 200 Vesey Street, 8th Floor,
New York, NY 10281-8098.

This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities, in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.

About Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
development and commercialization of innovative therapies for diseases
and conditions of the eye using its proprietary hydrogel platform
technology. Ocular Therapeutix's lead product candidates are in Phase 3
clinical development for post-surgical ocular inflammation and pain and
Phase 2 clinical development for glaucoma, ocular hypertension and
allergic conjunctivitis. The Company is also evaluating
sustained-release injectable anti-VEGF drug depots for back-of-the-eye
diseases. Ocular Therapeutix's first product, ReSure® Sealant, was
approved by the U.S. Food and Drug Administration in January 2014 to
seal corneal incisions following cataract surgery.